IRF1 and melanoma: In particular, nuclear expression of the IFNγ transcription factor IRF1 (25) is associated with better response to anti-PD-1 therapy in melanoma (26) and loss-of-function mutations in IFNγ pathway modulators (JAK1, JAK2) are associated with resistance to anti-PD-1 treatment.